Nyström C, Hällström T
Acta Psychiatr Scand. 1987 Apr;75(4):377-82. doi: 10.1111/j.1600-0447.1987.tb02805.x.
Seventy-five outpatients with major depressive disorder (RDC) were randomly referred to treatment with a dominant serotonin (5-HT) reuptake blocker (zimeldine, 100 mg, b.i.d. n = 40) or a dominant noradrenaline (NA) reuptake blocker (maprotiline, 75 mg, b.i.d. n = 35). Seven patients on each drug were non-responders after up to 4 weeks of treatment and were after a washout week crossed over to the other drug for up to another 8 weeks of treatment. There was a significant and similar improvement after 4 weeks of treatment with the second drug. After up to 8 weeks of treatment all patients but one in each group were much improved with the second drug. The existence of two biochemical subgroups of depression is discussed.
75名患有重度抑郁症（研究诊断标准）的门诊患者被随机分配接受主要作用于5-羟色胺（5-HT）再摄取阻滞剂（齐美利定，100毫克，每日两次，n = 40）或主要作用于去甲肾上腺素（NA）再摄取阻滞剂（马普替林，75毫克，每日两次，n = 35）治疗。每种药物治疗的患者中有7名在长达4周的治疗后无反应，在经过1周的洗脱期后，转而接受另一种药物治疗长达8周。使用第二种药物治疗4周后有显著且相似的改善。在长达8周的治疗后，每组除一名患者外的所有患者使用第二种药物后病情均有明显改善。文中讨论了抑郁症存在两个生化亚组的情况。
